In order to determine whether auto antibodies were restricted to some subtypes of epilepsy, we included 81 unselected epileptic patients and 81 controls, studied clinical data, EEG, neuroimaging, measured antinuclear (ANA), anticardiolipin (aCL) and ␤2GP1 antibodies.
INTRODUCTION
The clinical features of central nervous system involvement of systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) include epilepsy 1, 2 and epilepsy is one of the diagnosis criteria of SLE 3 . Epilepsy in SLE could be associated with a higher titer of antiphospholipid antibodies (APA) [4] [5] [6] . An association between antinuclear (ANA), anticardiolipin antibodies (aCL) and epilepsy, even in patients without SLE or APS has been postulated [7] [8] [9] [10] [11] . Some studies pointed out that the presence of auto antibodies could be restricted to partial or uncontrolled epilepsy 8, 9 , suggesting the existence of different subtypes of epileptic syndromes with different abnormalities of the immune system. We conducted this prospective study in order to clarify the relationship between epilepsy, auto antibodies and anticonvulsants in unselected epileptic adults.
PATIENTS AND METHODS

Patients
Eighty-one epileptic patients over 15 years old and 81 controls from the internal department of the 'Percy' Military Hospital and from the 'Jean Julliard' Military Blood Center (Clamart, France) were included from June 1997 to June 1999. Blood samples were obtained after informed consent. Controls were matched for sex and age and should be taking no drugs. For each patient, the latest neuroimaging, electroencephalographic studies and clinical records were prospectively studied before having knowledge of laboratory results. Patients and controls were screened for signs of SLE, APS or other autoimmune disorders. Epilepsy was categorised according to the International Classification of Epilepsies and Epileptic Syndromes 12 .
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STATISTICAL ANALYSIS
With an estimated prevalence of ANA and aCL antibodies in the general population (5, 4%) and among epileptic patients (25, 20%) 7-9, 13, 14 , we calculated that 80 patients were needed in each group to detect such a difference with 90% certainty and a 5% significance level 15 . We estimated the Odds Ratio (OR) using the Mac Nemar test with one degree of freedom 15 . All reported P-values were two-sided.
RESULTS
Median age was 33 years. Seventy-four patients had active epilepsy and 42 symptomatic seizures. Generalised epilepsy occurred in 68 patients, partial epilepsy in 9 patients and multiple seizure in 4 patients. Forty-two patients had symptomatic seizure and 39 patients had epilepsy of unknown causes. Twenty-seven epileptic patients were taking antiepileptic drugs and 31 patients a treatment implicated in SLE. No patient had features suggestive of SLE, APS or autoimmune disease.
Auto antibodies were detected at the same frequency and the same level in epileptic patients compared with controls, in epileptic patients treated either with antiepileptic medication or with implicated drugs in SLE and in different subtypes of seizure (Table 1) . ANA tended to be more frequent when patients had more than 10 seizures per year.
LA was positive in one patient (aCL+) and VDRL in one patient who had no other immunologic abnormality. Hemoglobin was under 110 g/l in 2 patients, none of them having auto antibodies. Platelet count was under 100 g/l in 5 patients (2 patients with a chronic unexplained thrombopenia aCL+, 3 patients with portal hypertension). PPT was above the normal range by at least 8 seconds in 3 patients (warfarin = 1, liver disease = 2).
DISCUSSION
Our data are in agreement with two surveys that strongly suggest that among epileptic patients, there were no consistent associations between auto antibodies and specific antiepileptic medications 7, 8 . Although we did not find any association between the prevalence of auto antibodies and epilepsy, it is relatively certain that there is a relationship between auto antibodies and epilepsy even in patients without SLE. In adults, IgG and IgM aCL antibodies were detected respectively in 31 and 68 of the 163 and 152 epileptic patients versus only in 3 and 6 of the 100 and 83 controls 7, 8 . Twenty-five and eighteen percent of these 163 and 152 epileptic patients versus 10 and 12% of the 100 and 83 controls were positive for ANA antibodies 7, 8 . Moreover, the frequency of auto antibodies depends on the type of epilepsy since aCL and ANA are more common in partial epilepsy 9 and in localisation-related epilepsy 8 . In a survey of children, almost 30% of patients with epilepsy were positive for at least one subtype of aCL 11 . In a study of 50 children and 20 healthy subjects a higher frequency of anti phospholipid antibodies was found in the study group (44%) compared with controls (10%) 10 . In these couple of studies, too, the positivity of auto antibodies were more frequent in symptomatic generalised epilepsy (32 and 71%) than in generalised idiopathic epilepsy (10 and 15%) 10, 11 . Our survey that included a weak proportion of partial epilepsy could explain why the frequency of aCL, ANA, ␤2GP1 antibodies was the same among epileptic patients and controls.
The finding of a greater prevalence of ANA and aCL in some forms of seizure disorder does not mean that these auto antibodies really play a role in the pathogenesis of epilepsy. First, too few convincing data regarding brain ischemia in SLE and non-SLE associated epilepsy have been published 16 . Unlike Rasmussen encephalitis associated epilepsy where antibodies to GluR3 have been demonstrated to promote in vitro neuronal cell death and to lead to induced seizures, antibodies directed to transmitter receptors have never been demonstrated in patients with SLE or epilepsy 16 . On the other hand, purified IgG containing APA can depolarise synaptoneurosomes from rat brainstem, suggesting this as a mechanism in central nervous system manifestations 17 . Finally, efficacy of intravenous immunoglobulins in the treatment of some drug-refractory seizures could support the immunogenetic hypothesis for these epilepsies 18 . However, further studies are needed to exactly determine what subsets of epilepsy could be immune-mediated.
